Advisory Board

//Advisory Board
Advisory Board2018-05-11T01:30:34+00:00

Dr. Stanley A. Plotkin, M.D., Scientific Advisory Board Member

Dr. Stanley A. Plotkin is Emeritus Professor of the University of Pennsylvania. Until 1991, he was Professor of Pediatrics and Microbiology at the University of Pennsylvania, Professor of Virology at the Wistar Institute and at the same time, Director of Infectious Diseases and Senior Physician at the Children’s Hospital of Philadelphia.

For seven years he was Medical and Scientific Director of Sanofi Pasteur, based at Marnes-la-Coquette, outside Paris.  He is now consultant to vaccine manufacturers and non-profit research organizations.

He is a member of the Institute of Medicine of the National Academy of Sciences and the French Academy of Medicine.  His bibliography includes over 700 articles and he has edited several books including a textbook on vaccines.  He developed the rubella vaccine now in standard use throughout the world, is codeveloper of the newly licensed pentavalent rotavirus vaccine, and has worked extensively on the development and application of other vaccines including anthrax, oral polio, rabies, varicella, and cytomegalovirus.

Dr. Louis Weiner, M.D, Scientific Advisory Board Member

Dr. Louis Weiner is director of Georgetown Lombardi Comprehensive Cancer Center. He holds the Francis L. and Charlotte G. Gragnani Chair and is professor of oncology at Georgetown University Medical Center.

He is responsible for the operation and development of the cancer center, including its research, clinical, and educational missions. The clinical mission includes leading the MedStar-Georgetown Cancer Institute in the metropolitan Washington area. Weiner is known for his laboratory and clinical research focusing on new therapeutic approaches that mobilize the patient’s immune system to fight cancer using monoclonal antibodies and other modalities of therapy.

Prior to joining Georgetown Lombardi as director in 2008, Weiner served as chairman of the medical oncology department and vice president for translational research at Fox Chase Cancer Center in Philadelphia, PA. He earned his bachelor degree in biology with honors from the University of Pennsylvania and his medical degree from Mount Sinai School of Medicine. After completing his internship, residency, and service as chief medical resident at the University of Vermont’s Medical Center Hospital, he held clinical and research fellowships in hematology and oncology at Tufts University School of Medicine in Boston. He serves as chair of the National Cancer Institute’s (NCI) Board of Scientific Counselors for Clinical Sciences and Epidemiology and as a member of the NCI Clinical Trials Advisory Committee (CTAC), and served on the NCI’s blue ribbon panel working group on immunotherapy and prevention to offer expert advice on the vision, goals and implementation of the National Cancer Moonshot Initiative. He also is a member of the Advisory Panel of the National Institutes of Health (NIH) Center for Scientific Research (CSR), which administers NIH research grants.

Dr. Richard B.S Roden, Ph.D, Scientific Advisory Board Member

Dr. Richard B.S Roden is Professor of Pathology, Oncology and Gynecology and Obstetrics and the Co-Leader of the Cancer Prevention and Control Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine.

For over 25 years, he has studied the biology of gynecologic cancer and approaches to prevent its development through vaccination. His early contributions to science include participating early in the development of human papillomavirus (HPV) L1 VLP vaccines while a postdoctoral fellow at the NCI. Dr. Roden then joined the faculty of the Johns Hopkins University 19 years ago.  Currently he is developing multimers of the minor capsid protein L2 and L1 VLP displaying the cross-protective epitope defined by his lab’s RG1 monoclonal antibody as a candidate pan-genotype preventive HPV vaccines. Two additional combination preventive and therapeutic HPV vaccines are also being prepared for clinical trial and Dr. Roden currently holds an IND. He is the co-leader of two projects in the Johns Hopkins Cervical Cancer SPORE. He has served as P.I. of several NIH/NCI-funded programs and projects including an RC2 and two RO1 grants. He co-chair the Fellowship Training Program Committee, serve on the Research Advisory Council and the Educational Advisory Committee in the Department of Pathology.

Mr. Danai Brooks, MBA, Financial Advisory Board

Mr. Danai Brooks is an experienced biotechnology executive, having led the turnaround and sale of Dyadic, a public industrial biotechnology company, to DuPont. While at Dyadic,

Mr. Brooks furthered the development of a C1-based vaccine program with Sanofi Pasteur and other partners.  He has been a featured speaker at major biotechnology industry conferences including the Global Biotechnology Congress, American Institute of Chemical Engineers and Pacific Rim Summit on Industrial Biotechnology.  In addition to his work in biotechnology, Mr. Brooks is the Managing Partner of Glen Echo Capital, a private equity firm that invests in lower middle market industrial and technology companies.  Earlier in his career, Mr. Brooks advised healthcare and industrial clients as an investment banker at J.P. Morgan, where he led mergers and acquisitions in excess of $40 billion.  Mr. Brooks holds a B.S. in Industrial Engineering and Master of Engineering from Cornell University, a Master of Engineering Management from Northwestern University and an MBA from Northwestern’s Kellogg School of Management.